In HR+/HER2− metastatic tumors, the PI3KCA mutations are present in around 40% of cases, and endocrine therapy and cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are the standards of care to treat these tumors. Here, CDK4 is linked to metastatic neoplasm.